ClinicalTrials.gg
CompletedNCT00735371Updated Jun 14, 2021Results posted

Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

A Phase 3 interventional study of LDX 30 mg and LDX 50 mg in Attention Deficit Hyperactivity Disorder (ADHD), sponsored by Shire. Completed at 45 sites in United States. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-06-14.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
314
Allocation
Randomized
Ages
13 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.

Enrollment
7th of 51
314 · median 48
Started
2008
with 8 others
Phase 3
15 of 51
none open now
Registered
12th of 51
by date
Lead sponsor
18 of 51
Shire

Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one is the 7th largest by enrollment, is one of 9 that started in 2008, is one of 15 in phase 3, and was the 12th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lisdexamfetamine

lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 13 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, or all of them as a file.
02

Study summary

The study will evaluate the efficacy of LDX treatment group compared to placebo on the change from Baseline ADHD-RS-IV score at endpoint.

03

Conditions studied

  • Attention Deficit Hyperactivity Disorder (ADHD)
04

Who can participate

Ages eligible
13 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet criteria for a primary diagnosis of ADHD
  • Baseline ADHD-RS-IV score >=28
  • BP w/in 95th percentile for age, gender, and height

Exclusion criteria

Exclusion Criteria:

  • Subject has controlled or uncontrolled comorbid psychiatric diagnosis
  • Subject has conduct disorder
  • Suicidal
  • Under or overweight
  • Concurrent chronic or acute illness that might confound results.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
314 participants (actual)

Study arms

  • Active comparator
    Lisdexamfetamine Dimesylate (LDX) 30 mg

    Drug: LDX 30 mg

  • Active comparator
    LDX 50 mg

    Drug: LDX 50 mg

  • Active comparator
    LDX 70 mg

    Drug: LDX 70 mg

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.

    Also known as: Vyvanse

  • DrugLDX 50 mg

    Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.

  • DrugLDX 70 mg

    Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.

  • DrugPlacebo

    Placebo will be identical to test product.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 4 Weeks

    The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.

    Time frame: Baseline and 1, 2, 3 and 4 weeks

Secondary outcomes

  1. Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores

    Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

    Time frame: 1, 2, 3 and 4 Weeks

  2. Youth Quality of Life-Research Version (YQOL-R) Total Score

    The Youth Quality of Life-research version (YQOL-R) is a validated 56-item generic instrument for comparing quality of life of adolescents across condition groups that scores each question on a scale from 0 (never) to 4 (very often). The YQOL scores are transformed to a 0-100 scale for easy interpretability. Higher scores indicate better quality of life.

    Time frame: Baseline and 4 weeks

07

Results

Posted Feb 23, 2010

Participant flow

Participant flow — Overall Study
MilestoneLisdexamfetamine Dimesylate (LDX) 30 mgLDX 50 mgLDX 70 mgPlacebo
Started78797879
Completed63666769
Not completed15131110
Withdrew: Adverse event3341
Withdrew: Protocol violation2203
Withdrew: Withdrawal by subject0220
Withdrew: Lost to follow-up1131
Withdrew: Lack of efficacy4204
Withdrew: Sponsor decision3101
Withdrew: Protocol violation0120
Withdrew: Prior vyvanse exposure1100
Withdrew: Exclusion criteria1000

Outcome measures

PrimaryChange From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 4 Weeks

The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.

Time frame:
Baseline and 1, 2, 3 and 4 weeks
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 4 Weeks
Units on a scaleLisdexamfetamine Dimesylate (LDX) 30 mgLDX 50 mgLDX 70 mgPlacebo
Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 4 Weeks-18.3 ± 1.25-21.1 ± 1.28-20.7 ± 1.25-12.8 ± 1.25
Statistical analysis
  • Lisdexamfetamine Dimesylate (LDX) 30 mg vs Placebo · ANCOVA · p = 0.0056
  • LDX 50 mg vs Placebo · ANCOVA · p = <0.0001
  • LDX 70 mg vs Placebo · ANCOVA · p = <0.0001
SecondaryNumber of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores

Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

Time frame:
1, 2, 3 and 4 Weeks
Reported as:
Number · Participants
Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores
ParticipantsLisdexamfetamine Dimesylate (LDX) 30 mgLDX 50 mgLDX 70 mgPlacebo
Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores44535730
Statistical analysis
  • Lisdexamfetamine Dimesylate (LDX) 30 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0235
  • LDX 50 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001
  • LDX 70 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001
SecondaryYouth Quality of Life-Research Version (YQOL-R) Total Score

The Youth Quality of Life-research version (YQOL-R) is a validated 56-item generic instrument for comparing quality of life of adolescents across condition groups that scores each question on a scale from 0 (never) to 4 (very often). The YQOL scores are transformed to a 0-100 scale for easy interpretability. Higher scores indicate better quality of life.

Time frame:
Baseline and 4 weeks
Reported as:
Mean · Units on a scale
Youth Quality of Life-Research Version (YQOL-R) Total Score
Units on a scaleLisdexamfetamine Dimesylate (LDX) 30 mgLDX 50 mgLDX 70 mgPlacebo
Baseline79.3 ± 10.0380.5 ± 10.6378.8 ± 15.3879.2 ± 11.08
4 Weeks81.1 ± 11.0981.3 ± 11.8681.3 ± 14.6681.3 ± 12.16

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lisdexamfetamine Dimesylate (LDX) 30 mg—0/78 (0%)51/78 (65.4%)
LDX 50 mg—0/77 (0%)53/77 (68.8%)
LDX 70 mg—0/78 (0%)56/78 (71.8%)
Placebo—0/77 (0%)38/77 (49.4%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventLisdexamfetamine Dimesylate (LDX) 30 mgLDX 50 mgLDX 70 mgPlacebo
Decreased appetiteMetabolism and nutrition disorders29/7821/7729/782/77
HeadacheNervous system disorders9/7813/7712/7810/77
Weight decreasedInvestigations3/787/7712/780/77
InsomniaPsychiatric disorders7/788/7711/783/77
IrritabilityGeneral disorders6/782/778/783/77
Upper respiratory tract infectionInfections and infestations2/784/774/786/77
Dry mouthGastrointestinal disorders0/786/774/781/77
DizzinessNervous system disorders1/784/775/783/77
NauseaGastrointestinal disorders1/783/775/782/77
Nasal congestionRespiratory, thoracic and mediastinal disorders1/780/775/781/77

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Lisdexamfetamine Dimesylate (LDX) 30 mgLDX 50 mgLDX 70 mgPlaceboTotal
<=18 years78797879314
Between 18 and 65 years00000
>=65 years00000
Age, Continuous
Age, Continuous(years)Lisdexamfetamine Dimesylate (LDX) 30 mgLDX 50 mgLDX 70 mgPlaceboTotal
Mean14.6 ± 1.3914.7 ± 1.2914.4 ± 1.3014.5 ± 1.2514.6 ± 1.31
Sex: Female, Male
Sex: Female, Male(Participants)Lisdexamfetamine Dimesylate (LDX) 30 mgLDX 50 mgLDX 70 mgPlaceboTotal
Female1916342594
Male59634454220
Region of Enrollment
Region of Enrollment(Participants)Lisdexamfetamine Dimesylate (LDX) 30 mgLDX 50 mgLDX 70 mgPlaceboTotal
United States78797879314
08

Study locations

45 sites
  • Clinical Study Centers, LLC
    Little Rock, Arkansas 72205, United States
  • Valley Clinical Research, Inc.
    El Centro, California 92243, United States
  • Peninsula Research Associates, Inc
    Rolling Hills Estates, California 90274, United States
  • Psychiatric Centers at San Diego (PCSD-Feighner Research Institute)
    San Diego, California 92108, United States
  • Elite Clinical Trials, Inc
    Wildomar, California 92595, United States
  • Florida Clinical Research Center, LLC
    Bradenton, Florida 34208, United States
  • Sarkis Clinical Trials
    Gainesville, Florida 32607, United States
  • Amedica Research Institute, Inc.
    Hialeah, Florida 33013, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32216, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32806-1122, United States
  • Miami Research Associates
    South Miami, Florida 33143, United States
  • Janus Center for Psychiatric Research
    West Palm Beach, Florida 33407, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30308, United States
  • Northwest Behavioral Research Center
    Marietta, Georgia 30060, United States
  • Capstone Clinical Research
    Libertyville, Illinois 60048, United States
  • Clinco Inc.
    Terre Haute, Indiana 47802, United States
  • Cientifica, Inc at Prairie View
    Newton, Kansas 67114, United States
  • Psychiatric Associates
    Overland Park, Kansas 66211, United States
  • Vince and Associates Clinical Research, Inc.
    Overland Park, Kansas 66212, United States
  • Pedia Research, LLC
    Owensboro, Kentucky 42301, United States
  • Four Rivers Clinical Research, Inc.
    Paducah, Kentucky 42003, United States
  • Louisiana Research Associates, Inc
    New Orleans, Louisiana 70114, United States
  • Bart Sangal, MD
    Troy, Michigan 48085, United States
  • Center for Psychiatry and Behavioral Medicine, Inc
    Las Vegas, Nevada 89128, United States
  • Children's Specialized Hospital
    Toms River, New Jersey 08755, United States
  • Bioscience Research, LLC
    Mount Kisco, New York 10549, United States
  • Triangle Neuropsychiatry, PLLC
    Durham, North Carolina 27707, United States
  • Innovis Health/Odyssey Research
    Fargo, North Dakota 58104, United States
  • University Hospitals of Cleveland Division of Child Adolescent Psychiatry
    Cleveland, Ohio 44106, United States
  • IPS Research Company
    Oklahoma City, Oklahoma 73103, United States
  • OCCI
    Eugene, Oregon 97401, United States
  • Summit Research Network
    Portland, Oregon 97210, United States
  • OCCI Inc
    Salem, Oregon 97301, United States
  • CRI Worldwide
    Philadelphia, Pennsylvania 19139, United States
  • Youth and Family Research Program/WP IC ADHD Research Program
    Pittsburgh, Pennsylvania 15213, United States
  • Valerie Arnold
    Memphis, Tennessee 38119, United States
  • FutureSearch Trials
    Austin, Texas 78756, United States
  • Bayou City Research, Ltd
    Houston, Texas 77007, United States
  • Red Oak Psychiatry Associates, PA
    Houston, Texas 77090, United States
  • ADHD Clinic of San Antonio
    San Antonio, Texas 78247, United States
  • Vermont Clinical Study Center
    Burlington, Vermont 05401, United States
  • Neuropsychiatric Associates
    Woodstock, Vermont 05091, United States
  • Neuroscience, Inc
    Herndon, Virginia 20170, United States
  • Dominion Clinical Research
    Midlothian, Virginia 23112, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98004, United States
09

References and documents

Publications

  • Findling RL, Childress AC, Cutler AJ, Gasior M, Hamdani M, Ferreira-Cornwell MC, Squires L. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011 Apr;50(4):395-405. doi: 10.1016/j.jaac.2011.01.007. Epub 2011 Mar 3. PubMed 21421179 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2008 to primary completion in Apr 2009, 5 months.

Results were first posted in Feb 2010, 10 months after primary completion.

Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 5 months is below that.

Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2008
First posted
Aug 14, 2008
StartActual
Oct 8, 2008
Primary completionActual
Apr 6, 2009
CompletionActual
Apr 6, 2009
Results first posted
Feb 23, 2010
Last update
Jun 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00735371
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Aug 14, 2008
Start date
Oct 8, 2008
Primary completion
Apr 6, 2009
Completion
Apr 6, 2009
Results posted
Feb 23, 2010
Last update
Jun 14, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion